Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1998 Oct;51(10):716–724. doi: 10.1136/jcp.51.10.716

Proliferation markers in tumours: interpretation and clinical value.

P J van Diest 1, G Brugal 1, J P Baak 1
PMCID: PMC500923  PMID: 10023332

Full text

PDF
716

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaltomaa S., Lipponen P., Eskelinen M., Kosma V. M., Marin S., Alhava E., Syrjänen K. Prognostic factors after 5 years follow-up in female breast cancer. Oncology. 1992;49(2):93–98. doi: 10.1159/000227019. [DOI] [PubMed] [Google Scholar]
  2. Aaltomaa S., Lipponen P., Papinaho S., Syrjänen K. Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer. J Cancer Res Clin Oncol. 1993;119(5):288–294. doi: 10.1007/BF01212727. [DOI] [PubMed] [Google Scholar]
  3. Aaltomaa S., Lipponen P., Syrjänen K. Nucleolar organizer regions related to morphometry, flow cytometry, sex steroid receptor content, tumour histology and prognosis in female breast cancer. Pathol Res Pract. 1993 May;189(4):416–421. doi: 10.1016/S0344-0338(11)80329-8. [DOI] [PubMed] [Google Scholar]
  4. Akerman M., Brandt L., Johnson A., Olsson H. Mitotic activity in non-Hodgkin's lymphoma. Relation to the Kiel classification and to prognosis. Br J Cancer. 1987 Feb;55(2):219–223. doi: 10.1038/bjc.1987.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Amada S., Nakano H., Tsuneyoshi M. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Int J Gynecol Pathol. 1995 Apr;14(2):134–142. [PubMed] [Google Scholar]
  6. Baak J. P., Chin D., van Diest P. J., Ortiz R., Matze-Cok P., Bacus S. S. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer. Lab Invest. 1991 Feb;64(2):215–223. [PubMed] [Google Scholar]
  7. Baak J. P., Fox H., Langley F. A., Buckley C. H. The prognostic value of morphometry in ovarian epithelial tumors of borderline malignancy. Int J Gynecol Pathol. 1985;4(3):186–191. doi: 10.1097/00004347-198509000-00003. [DOI] [PubMed] [Google Scholar]
  8. Baak J. P., Kurver P. H., De Snoo-Niewlaat A. J., De Graef S., Makkink B., Boon M. E. Prognostic indicators in breast cancer--morphometric methods. Histopathology. 1982 May;6(3):327–339. doi: 10.1111/j.1365-2559.1982.tb02727.x. [DOI] [PubMed] [Google Scholar]
  9. Baak J. P. Mitosis counting in tumors. Hum Pathol. 1990 Jul;21(7):683–685. doi: 10.1016/0046-8177(90)90026-2. [DOI] [PubMed] [Google Scholar]
  10. Baak J. P., Schipper N. W., Wisse-Brekelmans E. C., Ceelen T., Bosman F. T., van Geuns H., Wils J. The prognostic value of morphometrical features and cellular DNA content in cis-platin treated late ovarian cancer patients. Br J Cancer. 1988 May;57(5):503–508. doi: 10.1038/bjc.1988.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Baak J. P., Van Dop H., Kurver P. H., Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer. 1985 Jul 15;56(2):374–382. doi: 10.1002/1097-0142(19850715)56:2<374::aid-cncr2820560229>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  12. Baak J. P., Wisse-Brekelmans E. C., Langley F. A., Talerman A., Delemarre J. F. Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours. J Clin Pathol. 1986 Dec;39(12):1340–1346. doi: 10.1136/jcp.39.12.1340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Baak J. P., van Diest P. J., Ariens A. T., van Beek M. W., Bellot S. M., Fijnheer J., van Gorp L. H., Kwee W. S., Los J., Peterse H. C. The Multicenter Morphometric Mammary Carcinoma Project (MMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands. Pathol Res Pract. 1989 Nov;185(5):664–670. doi: 10.1016/S0344-0338(89)80213-4. [DOI] [PubMed] [Google Scholar]
  14. Barbareschi M., Girlando S., Mauri F. M., Forti S., Eccher C., Mauri F. A., Togni R., Dalla Palma P., Doglioni C. Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am J Clin Pathol. 1994 Aug;102(2):171–175. doi: 10.1093/ajcp/102.2.171. [DOI] [PubMed] [Google Scholar]
  15. Barnard N. J., Hall P. A., Lemoine N. R., Kadar N. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol. 1987 Aug;152(4):287–295. doi: 10.1002/path.1711520407. [DOI] [PubMed] [Google Scholar]
  16. Barrans S., Randerson J., Evans P., Blythe D., Shiach C., Child J. A., Morgan G., Jack A. S. Heterogeneity in cell proliferation and expression of p53 and bcl-2 during the indolent phase of germinal centre cell lymphoma: an explanation for clinical variability. Br J Haematol. 1995 Aug;90(4):830–836. doi: 10.1111/j.1365-2141.1995.tb05203.x. [DOI] [PubMed] [Google Scholar]
  17. Beck T., Weller E. E., Weikel W., Brumm C., Wilkens C., Knapstein P. G. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol. 1995 Apr;57(1):96–104. doi: 10.1006/gyno.1995.1104. [DOI] [PubMed] [Google Scholar]
  18. Beliën J. A., Baak J. P., van Diest P. J., van Ginkel A. H. Counting mitoses by image processing in Feulgen stained breast cancer sections: the influence of resolution. Cytometry. 1997 Jun 1;28(2):135–140. [PubMed] [Google Scholar]
  19. Bell D. A., Weinstock M. A., Scully R. E. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer. 1988 Nov 15;62(10):2212–2222. doi: 10.1002/1097-0142(19881115)62:10<2212::aid-cncr2820621024>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  20. Bell S. W., Kempson R. L., Hendrickson M. R. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994 Jun;18(6):535–558. [PubMed] [Google Scholar]
  21. Bergers E., Baak J. P., van Diest P. J., van Gorp L. H., Kwee W. S., Los J., Peterse H. L., Ruitenberg H. M., Schapers R. F., Somsen J. G. Prognostic implications of different cell cycle analysis models of flow cytometric DNA histograms of 1,301 breast cancer patients: results from the Multicenter Morphometric Mammary Carcinoma Project (MMMCP). Int J Cancer. 1997 Jun 20;74(3):260–269. doi: 10.1002/(sici)1097-0215(19970620)74:3<260::aid-ijc5>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  22. Bergers E., Jannink I., van Diest P. I., Cuesta M. A., Meyer S., van Mourik J. C., Baak J. P. The influence of fixation delay on mitotic activity and flow cytometric cell cycle variables. Hum Pathol. 1997 Jan;28(1):95–100. doi: 10.1016/s0046-8177(97)90286-0. [DOI] [PubMed] [Google Scholar]
  23. Bergers E., Montironi R., van Diest P. J., Prete E., Baak J. P. Interlaboratory reproducibility of semiautomated cell cycle analysis of flow cytometry DNA-histograms obtained from fresh material of 1,295 breast cancer cases. Hum Pathol. 1996 Jun;27(6):553–560. doi: 10.1016/s0046-8177(96)90161-6. [DOI] [PubMed] [Google Scholar]
  24. Bergers E., van Diest P. J., Baak J. P. Comparison of five cell cycle analysis models applied to 1414 flow cytometric DNA histograms of fresh frozen breast cancer. Cytometry. 1997 Feb 15;30(1):54–60. [PubMed] [Google Scholar]
  25. Bergers E., van Diest P. J., Baak J. P. Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry. J Clin Pathol. 1996 Nov;49(11):931–937. doi: 10.1136/jcp.49.11.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Biesterfeld S., Noll I., Noll E., Wohltmann D., Böcking A. Mitotic frequency as a prognostic factor in breast cancer. Hum Pathol. 1995 Jan;26(1):47–52. doi: 10.1016/0046-8177(95)90113-2. [DOI] [PubMed] [Google Scholar]
  27. Bigras G., Marcelpoil R., Brambilla E., Brugal G. Interest of targeting AgNORs measurement in cycling cells: in vivo cell kinetic evaluation of non-small cell lung cancer. Anal Cell Pathol. 1996 Aug;11(3):183–198. [PubMed] [Google Scholar]
  28. Bonsing B. A., Beerman H., Kuipers-Dijkshoorn N., Fleuren G. J., Cornelisse C. J. High levels of DNA index heterogeneity in advanced breast carcinomas. Evidence for DNA ploidy differences between lymphatic and hematogenous metastases. Cancer. 1993 Jan 15;71(2):382–391. doi: 10.1002/1097-0142(19930115)71:2<382::aid-cncr2820710219>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  29. Bosari S., Lee A. K., Tahan S. R., Figoni M. A., Wiley B. D., Heatley G. J., Silverman M. L. DNA flow cytometric analysis and prognosis of axillary lymph node-negative breast carcinoma. Cancer. 1992 Oct 1;70(7):1943–1950. doi: 10.1002/1097-0142(19921001)70:7<1943::aid-cncr2820700722>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  30. Bouzubar N., Walker K. J., Griffiths K., Ellis I. O., Elston C. W., Robertson J. F., Blamey R. W., Nicholson R. I. Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer. 1989 Jun;59(6):943–947. doi: 10.1038/bjc.1989.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Bulten J., van der Laak J. A., Gemmink J. H., Pahlplatz M. M., de Wilde P. C., Hanselaar A. G. MIB1, a promising marker for the classification of cervical intraepithelial neoplasia. J Pathol. 1996 Mar;178(3):268–273. doi: 10.1002/(SICI)1096-9896(199603)178:3<268::AID-PATH482>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
  32. Carrillo R., Candia A., Rodriguez-Peralto J. L., Caz V. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol. 1997 Feb;28(2):160–165. doi: 10.1016/s0046-8177(97)90100-3. [DOI] [PubMed] [Google Scholar]
  33. Celis J. E., Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci U S A. 1985 May;82(10):3262–3266. doi: 10.1073/pnas.82.10.3262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Choong P. F., Akerman M., Willén H., Andersson C., Gustafson P., Alvegård T., Rydholm A. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotype-specific? APMIS. 1995 Nov;103(11):797–805. doi: 10.1111/j.1699-0463.1995.tb01437.x. [DOI] [PubMed] [Google Scholar]
  35. Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer. 1991 Sep 15;68(6):1309–1317. doi: 10.1002/1097-0142(19910915)68:6<1309::aid-cncr2820680621>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  36. Coindre J. M., Trojani M., Contesso G., David M., Rouesse J., Bui N. B., Bodaert A., De Mascarel I., De Mascarel A., Goussot J. F. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer. 1986 Jul 15;58(2):306–309. doi: 10.1002/1097-0142(19860715)58:2<306::aid-cncr2820580216>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  37. Collan Y. U., Kuopio T., Baak J. P., Becker R., Bogomoletz W. V., Deverell M., van Diest P., van Galen C., Gilchrist K., Javed A. Standardized mitotic counts in breast cancer. Evaluation of the method. Pathol Res Pract. 1996 Sep;192(9):931–941. doi: 10.1016/S0344-0338(96)80075-6. [DOI] [PubMed] [Google Scholar]
  38. Collin F., Chassevent A., Bonichon F., Bertrand G., Terrier P., Coindra J. M. Flow cytometric DNA content analysis of 185 soft tissue neoplasms indicates that S-phase fraction is a prognostic factor for sarcomas. French Federation of Cancer Centers (FNCLCC) Sarcoma Group. Cancer. 1997 Jun 15;79(12):2371–2379. doi: 10.1002/(sici)1097-0142(19970615)79:12<2371::aid-cncr11>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  39. Coons S. W., Johnson P. C. Regional heterogeneity in the DNA content of human gliomas. Cancer. 1993 Nov 15;72(10):3052–3060. doi: 10.1002/1097-0142(19931115)72:10<3052::aid-cncr2820721030>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  40. Cuvelier C. A., Roels H. J. Cytophotometric studies of the nuclear DNA content in cartilaginous tumors. Cancer. 1979 Oct;44(4):1363–1374. doi: 10.1002/1097-0142(197910)44:4<1363::aid-cncr2820440430>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  41. Daumas-Duport C., Scheithauer B., O'Fallon J., Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer. 1988 Nov 15;62(10):2152–2165. doi: 10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  42. Dellas A., Schultheiss E., Holzgreve W., Oberholzer M., Torhorst J., Gudat F. Investigation of the Bcl-2 and C-myc expression in relationship to the Ki-67 labelling index in cervical intraepithelial neoplasia. Int J Gynecol Pathol. 1997 Jul;16(3):212–218. doi: 10.1097/00004347-199707000-00004. [DOI] [PubMed] [Google Scholar]
  43. Dervan P. A., Gilmartin L. G., Loftus B. M., Carney D. N. Breast carcinoma kinetics. Argyrophilic nucleolar organizer region counts correlate with Ki67 scores. Am J Clin Pathol. 1989 Oct;92(4):401–407. doi: 10.1093/ajcp/92.4.401. [DOI] [PubMed] [Google Scholar]
  44. Dettmar P., Harbeck N., Thomssen C., Pache L., Ziffer P., Fizi K., Jänicke F., Nathrath W., Schmitt M., Graeff H. Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer. 1997;75(10):1525–1533. doi: 10.1038/bjc.1997.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Di Stefano D., Mingazzini P. L., Scucchi L., Donnetti M., Marinozzi V. A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki-67 immunostaining, and nucleolar organizer region-associated proteins in human breast cancer. Cancer. 1991 Jan 15;67(2):463–471. doi: 10.1002/1097-0142(19910115)67:2<463::aid-cncr2820670224>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  46. Di Vinci A., Geido E., Pfeffer U., Vidali G., Giaretti W. Quantitative analysis of mitotic and early-G1 cells using monoclonal antibodies against the AF-2 protein. Cytometry. 1993;14(4):421–427. doi: 10.1002/cyto.990140411. [DOI] [PubMed] [Google Scholar]
  47. Donhuijsen K., Schmidt U., Hirche H., van Beuningen D., Budach V. Changes in mitotic rate and cell cycle fractions caused by delayed fixation. Hum Pathol. 1990 Jul;21(7):709–714. doi: 10.1016/0046-8177(90)90030-9. [DOI] [PubMed] [Google Scholar]
  48. Drobnjak M., Latres E., Pollack D., Karpeh M., Dudas M., Woodruff J. M., Brennan M. F., Cordon-Cardo C. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst. 1994 Apr 6;86(7):549–554. doi: 10.1093/jnci/86.7.549. [DOI] [PubMed] [Google Scholar]
  49. Elston C. W., Ellis I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 Nov;19(5):403–410. doi: 10.1111/j.1365-2559.1991.tb00229.x. [DOI] [PubMed] [Google Scholar]
  50. Eskelinen M., Lipponen P., Papinaho S., Aaltomaa S., Kosma V. M., Klemi P., Syrjänen K. DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer. Int J Cancer. 1992 Jun 19;51(4):555–561. doi: 10.1002/ijc.2910510409. [DOI] [PubMed] [Google Scholar]
  51. Evans H. L., Ayala A. G., Romsdahl M. M. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer. 1977 Aug;40(2):818–831. doi: 10.1002/1097-0142(197708)40:2<818::aid-cncr2820400234>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  52. Gerdes J., Stein H., Pileri S., Rivano M. T., Gobbi M., Ralfkiaer E., Nielsen K. M., Pallesen G., Bartels H., Palestro G. Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet. 1987 Aug 22;2(8556):448–449. doi: 10.1016/s0140-6736(87)90977-9. [DOI] [PubMed] [Google Scholar]
  53. Going J. J. Efficiently estimated histologic cell counts. Hum Pathol. 1994 Apr;25(4):333–336. doi: 10.1016/0046-8177(94)90139-2. [DOI] [PubMed] [Google Scholar]
  54. Griffin N. R., Howard M. R., Quirke P., O'Brien C. J., Child J. A., Bird C. C. Prognostic indicators in centroblastic-centrocytic lymphoma. J Clin Pathol. 1988 Aug;41(8):866–870. doi: 10.1136/jcp.41.8.866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Grogan T. M., Lippman S. M., Spier C. M., Slymen D. J., Rybski J. A., Rangel C. S., Richter L. C., Miller T. P. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood. 1988 Apr;71(4):1157–1160. [PubMed] [Google Scholar]
  56. Guillaud P., du Manoir S., Seigneurin D. Quantification and topographical description of Ki-67 antibody labelling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7). Anal Cell Pathol. 1989 Feb;1(1):25–39. [PubMed] [Google Scholar]
  57. Haapasalo H., Collan Y., Atkin N. B., Pesonen E., Seppä A. Prognosis of ovarian carcinomas: prediction by histoquantitative methods. Histopathology. 1989 Aug;15(2):167–178. doi: 10.1111/j.1365-2559.1989.tb03064.x. [DOI] [PubMed] [Google Scholar]
  58. Haapasalo H., Collan Y., Seppä A., Gidlund A. L., Atkin N. B., Pesonen E. Prognostic value of ovarian carcinoma grading methods--a method comparison study. Histopathology. 1990 Jan;16(1):1–7. doi: 10.1111/j.1365-2559.1990.tb01053.x. [DOI] [PubMed] [Google Scholar]
  59. Haapasalo H., Pesonen E., Collan Y. Volume corrected mitotic index (M/V-INDEX). The standard of mitotic activity in neoplasms. Pathol Res Pract. 1989 Nov;185(5):551–554. doi: 10.1016/S0344-0338(89)80191-8. [DOI] [PubMed] [Google Scholar]
  60. Hall P. A., Levison D. A. Review: assessment of cell proliferation in histological material. J Clin Pathol. 1990 Mar;43(3):184–192. doi: 10.1136/jcp.43.3.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Hall P. A., Levison D. A. Review: assessment of cell proliferation in histological material. J Clin Pathol. 1990 Mar;43(3):184–192. doi: 10.1136/jcp.43.3.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Hall P. A., Richards M. A., Gregory W. M., d'Ardenne A. J., Lister T. A., Stansfeld A. G. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol. 1988 Mar;154(3):223–235. doi: 10.1002/path.1711540305. [DOI] [PubMed] [Google Scholar]
  63. Isola J. J., Helin H. J., Helle M. J., Kallioniemi O. P. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer. 1990 Mar 1;65(5):1180–1184. doi: 10.1002/1097-0142(19900301)65:5<1180::aid-cncr2820650525>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  64. Jacob R., Welkoborsky H. J., Mann W. J., Höfken F., Dienes H. P., Freije J. E. Heterogeneity of squamous cell carcinomas of the head and neck--analysis of tumor biologic factors and proliferation rates. Laryngoscope. 1996 Sep;106(9 Pt 1):1170–1175. doi: 10.1097/00005537-199609000-00023. [DOI] [PubMed] [Google Scholar]
  65. Jannink I., Risberg B., Van Diest P. J., Baak J. P. Heterogeneity of mitotic activity in breast cancer. Histopathology. 1996 Nov;29(5):421–428. doi: 10.1046/j.1365-2559.1996.d01-509.x. [DOI] [PubMed] [Google Scholar]
  66. Jeffers M. D., Oakes S. J., Richmond J. A., Macaulay E. M. Proliferation, ploidy and prognosis in uterine smooth muscle tumours. Histopathology. 1996 Sep;29(3):217–223. doi: 10.1111/j.1365-2559.1996.tb01394.x. [DOI] [PubMed] [Google Scholar]
  67. Jensen V., Ladekarl M., Holm-Nielsen P., Melsen F., Soerensen F. B. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. J Pathol. 1995 Aug;176(4):343–352. doi: 10.1002/path.1711760405. [DOI] [PubMed] [Google Scholar]
  68. Joensuu H., Toikkanen S., Klemi P. J. DNA index and S-phase fraction and their combination as prognostic factors in operable ductal breast carcinoma. Cancer. 1990 Jul 15;66(2):331–340. doi: 10.1002/1097-0142(19900715)66:2<331::aid-cncr2820660222>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  69. Kallioniemi O. P., Visakorpi T., Holli K., Heikkinen A., Isola J., Koivula T. Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. Cytometry. 1991;12(5):413–421. doi: 10.1002/cyto.990120506. [DOI] [PubMed] [Google Scholar]
  70. Kaman E. J., Smeulders A. W., Verbeek P. W., Young I. T., Baak J. P. Image processing for mitoses in sections of breast cancer: a feasibility study. Cytometry. 1984 May;5(3):244–249. doi: 10.1002/cyto.990050305. [DOI] [PubMed] [Google Scholar]
  71. Kressner U., Lindmark G., Gerdin B., Pahlman L., Glimelius B. Heterogeneity in proliferation markers in colorectal cancer. Anticancer Res. 1995 Nov-Dec;15(6B):2755–2761. [PubMed] [Google Scholar]
  72. Kühn W., Kaufmann M., Feichter G. E., Schmid H., Hanke J., Rummel H. H. Psammomabody content and DNA-flow cytometric results as prognostic factors in advanced ovarian carcinoma. Eur J Gynaecol Oncol. 1988;9(3):234–241. [PubMed] [Google Scholar]
  73. Larson B., Silfverswärd C., Nilsson B., Pettersson F. Prognostic factors in uterine leiomyosarcoma. A clinical and histopathological study of 143 cases. The Radiumhemmet series 1936-1981. Acta Oncol. 1990;29(2):185–191. doi: 10.3109/02841869009126543. [DOI] [PubMed] [Google Scholar]
  74. Le Doussal V., Tubiana-Hulin M., Friedman S., Hacene K., Spyratos F., Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989 Nov 1;64(9):1914–1921. doi: 10.1002/1097-0142(19891101)64:9<1914::aid-cncr2820640926>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  75. Lee A. K., Wiley B., Dugan J. M., Hamilton W. H., Loda M., Heatley G. J., Cook L., Silverman M. L. Quantitative DNA analysis and proliferation in breast carcinomas. A comparison between image analysis and flow cytometry. Pathol Res Pract. 1992 Jun;188(4-5):428–432. doi: 10.1016/S0344-0338(11)80032-4. [DOI] [PubMed] [Google Scholar]
  76. Leonardi E., Girlando S., Serio G., Mauri F. A., Perrone G., Scampini S., Dalla Palma P., Barbareschi M. PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables. J Clin Pathol. 1992 May;45(5):416–419. doi: 10.1136/jcp.45.5.416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Levine E. A., Holzmayer T., Bacus S., Mechetner E., Mera R., Bolliger C., Roninson I. B., Das Gupta T. K. Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol. 1997 Oct;15(10):3249–3257. doi: 10.1200/JCO.1997.15.10.3249. [DOI] [PubMed] [Google Scholar]
  78. Lipponen P. K., Collan Y., Eskelinen M. J. Volume corrected mitotic index (M/V index), mitotic activity index (MAI), and histological grading in breast cancer. Int Surg. 1991 Oct-Dec;76(4):245–249. [PubMed] [Google Scholar]
  79. MacGrogan G., Mauriac L., Durand M., Bonichon F., Trojani M., de Mascarel I., Coindre J. M. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer. 1996 Nov;74(9):1458–1465. doi: 10.1038/bjc.1996.565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Marchetti E., Querzoli P., Marzola A., Bagni A., Ferretti S., Fabris G., Nenci I. Assessment of proliferative rate of breast cancer by Ki-67 monoclonal antibody. Mod Pathol. 1990 Jan;3(1):31–35. [PubMed] [Google Scholar]
  81. McCluggage W. G., Buhidma M., Tang L., Maxwell P., Bharucha H. Monoclonal antibody MIB1 in the assessment of cervical squamous intraepithelial lesions. Int J Gynecol Pathol. 1996 Apr;15(2):131–136. doi: 10.1097/00004347-199604000-00007. [DOI] [PubMed] [Google Scholar]
  82. Meyer J. S., McDivitt R. W. Reliability and stability of the thymidine labeling index of breast carcinoma. Lab Invest. 1986 Feb;54(2):160–164. [PubMed] [Google Scholar]
  83. Michie B. A., Black C., Reid R. P., Barrett A., Hamblen D. L. Image analysis derived ploidy and proliferation indices in soft tissue sarcomas: comparison with clinical outcome. J Clin Pathol. 1994 May;47(5):443–447. doi: 10.1136/jcp.47.5.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Montironi R., Diamanti L., Santinelli A., Magi Galluzzi C., Scarpelli M., Giannulis I., Mangili F. Computed cell cycle and DNA histogram analyses in image cytometry in breast cancer. J Clin Pathol. 1993 Sep;46(9):795–800. doi: 10.1136/jcp.46.9.795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Mourad W. A., Erkman-Balis B., Livingston S., Shoukri M., Cox C. E., Nicosia S. V., Rowlands D. T., Jr Argyrophilic nucleolar organizer regions in breast carcinoma. Correlation with DNA flow cytometry, histopathology, and lymph node status. Cancer. 1992 Apr 1;69(7):1739–1744. doi: 10.1002/1097-0142(19920401)69:7<1739::aid-cncr2820690715>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  86. Mouriquand J., Gozlan-Fior M., Villemain D., Bouchet Y., Sage J. C., Mermet M. A., Bolla M. Value of cytoprognostic classification in breast carcinomas. J Clin Pathol. 1986 May;39(5):489–496. doi: 10.1136/jcp.39.5.489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Myhre-Jensen O., Kaae S., Madsen E. H., Sneppen O. Histopathological grading in soft-tissue tumours. Relation to survival in 261 surgically treated patients. Acta Pathol Microbiol Immunol Scand A. 1983 Mar;91(2):145–150. [PubMed] [Google Scholar]
  88. Müller W., Schneiders A., Meier S., Hommel G., Gabbert H. E. Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br J Cancer. 1996 Sep;74(5):759–765. doi: 10.1038/bjc.1996.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Ofner D., Hittmair A., Marth C., Ofner C., Tötsch M., Daxenbichler G., Mikuz G., Margreiter R., Schmid K. W. Relationship between quantity of silver stained nucleolar organizer regions associated proteins (Ag-NORs) and population doubling time in ten breast cancer cell lines. Pathol Res Pract. 1992 Aug;188(6):742–746. doi: 10.1016/S0344-0338(11)80171-8. [DOI] [PubMed] [Google Scholar]
  90. Oudejans J. J., Jiwa N. M., Kummer J. A., Ossenkoppele G. J., van Heerde P., Baars J. W., Kluin P. M., Kluin-Nelemans J. C., van Diest P. J., Middeldorp J. M. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood. 1997 Feb 15;89(4):1376–1382. [PubMed] [Google Scholar]
  91. Payne S., Kernohan N. M., Walker F. Proliferation in the normal cervix and in preinvasive cervical lesions. J Clin Pathol. 1996 Aug;49(8):667–671. doi: 10.1136/jcp.49.8.667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Pietiläinen T., Lipponen P., Aaltomaa S., Eskelinen M., Kosma V. M., Syrjänen K. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol. 1996;122(11):687–692. doi: 10.1007/BF01209033. [DOI] [PubMed] [Google Scholar]
  93. Polkowski W., Meijer G. A., Baak J. P., ten Kate F. J., Obertop H., Offerhaus G. J., van Lanschot J. J. Reproducibility of p53 and Ki-67 immunoquantitation in Barrett's esophagus. Anal Quant Cytol Histol. 1997 Jun;19(3):246–254. [PubMed] [Google Scholar]
  94. Prayson R. A., Hart W. R. Mitotically active leiomyomas of the uterus. Am J Clin Pathol. 1992 Jan;97(1):14–20. doi: 10.1093/ajcp/97.1.14. [DOI] [PubMed] [Google Scholar]
  95. Rodenburg C. J., Cornelisse C. J., Hermans J., Fleuren G. J. DNA flow cytometry and morphometry as prognostic indicators in advanced ovarian cancer: a step forward in predicting the clinical outcome. Gynecol Oncol. 1988 Feb;29(2):176–187. doi: 10.1016/0090-8258(88)90212-0. [DOI] [PubMed] [Google Scholar]
  96. Roessler K., Nasel C., Czech T., Matula C., Lassmann H., Koos W. T. Histological heterogeneity of neuroradiologically suspected adult low grade gliomas detected by Xenon enhanced computerized tomography (CT). Acta Neurochir (Wien) 1996;138(11):1341–1347. doi: 10.1007/BF01411065. [DOI] [PubMed] [Google Scholar]
  97. Rudolph P., Kellner U., Chassevent A., Collin F., Bonichon F., Parwaresch R., Coindre J. M. Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma. A multivariate study. Am J Pathol. 1997 Jun;150(6):1997–2007. [PMC free article] [PubMed] [Google Scholar]
  98. Ruiter D. J., Cornelisse C. J., van Rijssel T. G., van der Velde E. A. Aneurysmal bone cyst and telangiectatic osteosarcoma. A histopathological and morphometric study. Virchows Arch A Pathol Anat Histol. 1977 Apr 29;373(4):311–325. doi: 10.1007/BF00432531. [DOI] [PubMed] [Google Scholar]
  99. Ruiter D. J., van Rijssel T. G., van der Velde E. A. Aneurysmal bone cysts: a clinicopathological study of 105 cases. Cancer. 1977 May;39(5):2231–2239. doi: 10.1002/1097-0142(197705)39:5<2231::aid-cncr2820390541>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  100. Röser B., Willén H., Hugoson A., Rydholm A. Prognostic factors in synovial sarcoma. Cancer. 1989 Jun 1;63(11):2182–2185. doi: 10.1002/1097-0142(19890601)63:11<2182::aid-cncr2820631120>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  101. Sahin A. A., Ro J., Ro J. Y., Blick M. B., el-Naggar A. K., Ordonez N. G., Fritsche H. A., Smith T. L., Hortobagyi G. N., Ayala A. G. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer. 1991 Aug 1;68(3):549–557. doi: 10.1002/1097-0142(19910801)68:3<549::aid-cncr2820680318>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  102. Schmidt R. A., Conrad E. U., 3rd, Collins C., Rabinovitch P., Finney A. Measurement and prediction of the short-term response of soft tissue sarcomas to chemotherapy. Cancer. 1993 Nov 1;72(9):2593–2601. doi: 10.1002/1097-0142(19931101)72:9<2593::aid-cncr2820720914>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  103. Schmitt F. C., Pereira E. M., Andrade L. M., Torresan M., de Lucca L. The proliferating cell nuclear antigen index in breast carcinomas does not correlate with mitotic index and estrogen receptor immunoreactivity. Pathol Res Pract. 1994 Sep;190(8):786–791. doi: 10.1016/s0344-0338(11)80426-7. [DOI] [PubMed] [Google Scholar]
  104. Schrape S., Jones D. B., Wright D. H. A comparison of three methods for the determination of the growth fraction in non-Hodgkin's lymphoma. Br J Cancer. 1987 Mar;55(3):283–286. doi: 10.1038/bjc.1987.54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Siitonen S. M., Kallioniemi O. P., Isola J. J. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer. Am J Pathol. 1993 Apr;142(4):1081–1089. [PMC free article] [PubMed] [Google Scholar]
  106. Silvestrini R., Daidone M. G., Luisi A., Mastore M., Leutner M., Salvadori B. Cell proliferation in 3,800 node-negative breast cancers: consistency over time of biological and clinical information provided by 3H-thymidine labelling index. Int J Cancer. 1997 Feb 20;74(1):122–127. doi: 10.1002/(sici)1097-0215(19970220)74:1<122::aid-ijc20>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  107. Simpson J. F., Dutt P. L., Page D. L. Expression of mitoses per thousand cells and cell density in breast carcinomas: a proposal. Hum Pathol. 1992 Jun;23(6):608–611. doi: 10.1016/0046-8177(92)90314-s. [DOI] [PubMed] [Google Scholar]
  108. Spina D., Leoncini L., Close P., Megha T., Pacenti L., Tosi P., Pileri S., Sabattini E., Kraft R., Laissue J. Growth vs. DNA strand breaks in Hodgkin's disease: impaired proliferative ability of Hodgkin and Reed-Sternberg cells. Int J Cancer. 1996 Apr 10;66(2):179–183. doi: 10.1002/(SICI)1097-0215(19960410)66:2<179::AID-IJC7>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  109. Sumithran E., Susil B. J., Looi L. M. The prognostic significance of grading in borderline mucinous tumors of the ovary. Hum Pathol. 1988 Jan;19(1):15–18. doi: 10.1016/s0046-8177(88)80310-1. [DOI] [PubMed] [Google Scholar]
  110. Tahan S. R., Neuberg D. S., Dieffenbach A., Yacoub L. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer. 1993 Jun 1;71(11):3552–3559. doi: 10.1002/1097-0142(19930601)71:11<3552::aid-cncr2820711115>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  111. Thomas M., Noguchi M., Kitagawa H., Kinoshita K., Miyazaki I. Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma. J Clin Pathol. 1993 Jun;46(6):525–528. doi: 10.1136/jcp.46.6.525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Tosi P., Luzi P., Sforza V., Santopietro R., Bindi M., Tucci E., Barbini P., Baak J. P. Correlation between morphometrical parameters and disease-free survival in ductal breast cancer treated only by surgery. Appl Pathol. 1986;4(1-2):33–42. [PubMed] [Google Scholar]
  113. Tubiana M., Pejovic M. H., Koscielny S., Chavaudra N., Malaise E. Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer. 1989 Jul 15;44(1):17–22. doi: 10.1002/ijc.2910440104. [DOI] [PubMed] [Google Scholar]
  114. Uyterlinde A. M., Baak J. P., Schipper N. W., Peterse H. J., Meijer J. W., Vooys P. G., Matze E. Prognostic value of morphometry and DNA flow-cytometry features of invasive breast cancers detected by population screening: comparison with control group of hospital patients. Int J Cancer. 1991 May 10;48(2):173–181. doi: 10.1002/ijc.2910480204. [DOI] [PubMed] [Google Scholar]
  115. Uyterlinde A. M., Schipper N. W., Baak J. P., Peterse H., Matze E. Limited prognostic value of cellular DNA content to classical and morphometrical parameters in invasive ductal breast cancer. Am J Clin Pathol. 1988 Mar;89(3):301–307. doi: 10.1093/ajcp/89.3.301. [DOI] [PubMed] [Google Scholar]
  116. VAN DER WERF-MESSING B., VAN UNNIK J. FIBROSARCOMA OF THE SOFT TISSUES: A CLINICOPATHOLOGIC STUDY. Cancer. 1965 Sep;18:1113–1123. doi: 10.1002/1097-0142(196509)18:9<1113::aid-cncr2820180911>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  117. Verhoeven D., Bourgeois N., Derde M. P., Kaufman L., Buyssens N. Comparison of cell growth in different parts of breast cancers. Histopathology. 1990 Dec;17(6):505–509. doi: 10.1111/j.1365-2559.1990.tb00789.x. [DOI] [PubMed] [Google Scholar]
  118. Veronese S. M., Gambacorta M., Gottardi O., Scanzi F., Ferrari M., Lampertico P. Proliferation index as a prognostic marker in breast cancer. Cancer. 1993 Jun 15;71(12):3926–3931. doi: 10.1002/1097-0142(19930615)71:12<3926::aid-cncr2820711221>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  119. Veronese S. M., Maisano C., Scibilia J. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res. 1995 Nov-Dec;15(6B):2717–2722. [PubMed] [Google Scholar]
  120. Visscher D. W., Wykes S., Kubus J., Crissman J. D. Comparison of PCNA/cyclin immunohistochemistry with flow cytometric S-phase fraction in breast cancer. Breast Cancer Res Treat. 1992;22(2):111–118. doi: 10.1007/BF01833340. [DOI] [PubMed] [Google Scholar]
  121. Walker R. A., Gallacher B. Determination of transforming growth factor beta 1 mRNA expression in breast carcinomas by in situ hybridization. J Pathol. 1995 Oct;177(2):123–127. doi: 10.1002/path.1711770204. [DOI] [PubMed] [Google Scholar]
  122. Weidner N., Moore D. H., 2nd, Ljung B. M., Waldman F. M., Goodson W. H., 3rd, Mayall B., Chew K., Smith H. S. Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade. Am J Surg Pathol. 1993 Oct;17(10):987–994. doi: 10.1097/00000478-199310000-00003. [DOI] [PubMed] [Google Scholar]
  123. Weidner N., Moore D. H., 2nd, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol. 1994 Apr;25(4):337–342. doi: 10.1016/0046-8177(94)90140-6. [DOI] [PubMed] [Google Scholar]
  124. Wintzer H. O., Zipfel I., Schulte-Mönting J., Hellerich U., von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer. 1991 Jan 15;67(2):421–428. doi: 10.1002/1097-0142(19910115)67:2<421::aid-cncr2820670217>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  125. Woosley J. T. Measuring cell proliferation. Arch Pathol Lab Med. 1991 Jun;115(6):555–557. [PubMed] [Google Scholar]
  126. Zucker R. M., Elstein K. H., Easterling R. E., Massaro E. J. Flow cytometric discrimination of mitotic nuclei by right-angle light scatter. Cytometry. 1988 May;9(3):226–231. doi: 10.1002/cyto.990090307. [DOI] [PubMed] [Google Scholar]
  127. de la Monte S. M., Flickinger J., Linggood R. M. Histopathologic features predicting recurrence of meningiomas following subtotal resection. Am J Surg Pathol. 1986 Dec;10(12):836–843. doi: 10.1097/00000478-198612000-00002. [DOI] [PubMed] [Google Scholar]
  128. ten Kate T. K., Beliën J. A., Smeulders A. W., Baak J. P. Method for counting mitoses by image processing in Feulgen stained breast cancer sections. Cytometry. 1993;14(3):241–250. doi: 10.1002/cyto.990140302. [DOI] [PubMed] [Google Scholar]
  129. van Dierendonck J. H., Wijsman J. H., Keijzer R., van de Velde C. J., Cornelisse C. J. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining. Am J Pathol. 1991 May;138(5):1165–1172. [PMC free article] [PubMed] [Google Scholar]
  130. van Diest P. J., Baak J. P., Matze-Cok P., Bacus S. S. Prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients with morphometry, DNA flow cytometry and HER-2/neu oncoprotein expression. Preliminary results. Pathol Res Pract. 1992 Apr;188(3):344–349. doi: 10.1016/S0344-0338(11)81215-X. [DOI] [PubMed] [Google Scholar]
  131. van Diest P. J., Baak J. P., Matze-Cok P., Wisse-Brekelmans E. C., van Galen C. M., Kurver P. H., Bellot S. M., Fijnheer J., van Gorp L. H., Kwee W. S. Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol. 1992 Jun;23(6):603–607. doi: 10.1016/0046-8177(92)90313-r. [DOI] [PubMed] [Google Scholar]
  132. van Diest P. J., van Dam P., Henzen-Logmans S. C., Berns E., van der Burg M. E., Green J., Vergote I. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol. 1997 Oct;50(10):801–804. doi: 10.1136/jcp.50.10.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. van Unnik J. A., Coindre J. M., Contesso C., Albus-Lutter C. E., Schiodt T., Sylvester R., Thomas D., Bramwell V., Mouridsen H. T. Grading of soft tissue sarcomas: experience of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 1993;29A(15):2089–2093. doi: 10.1016/0959-8049(93)90039-i. [DOI] [PubMed] [Google Scholar]
  134. van de Schepop H. A., de Jong J. S., van Diest P. J., Baak J. P. Counting of apoptotic cells: a methodological study in invasive breast cancer. Clin Mol Pathol. 1996 Aug;49(4):M214–M217. doi: 10.1136/mp.49.4.m214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. van der Linden J. C., Baak J. P., Lindeman J., Hermans J., Meyer C. J. Prospective evaluation of prognostic value of morphometry in patients with primary breast cancer. J Clin Pathol. 1987 Mar;40(3):302–306. doi: 10.1136/jcp.40.3.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. van der Linden J. C., Lindeman J., Baak J. P., Meijer C. J., Herman C. J. The Multivariate Prognostic Index and nuclear DNA content are independent prognostic factors in primary breast cancer patients. Cytometry. 1989 Jan;10(1):56–61. doi: 10.1002/cyto.990100110. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES